Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255879 · ClinicalTrials.gov registry record · Phase 1
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
A Phase 1 study of Dyskinesia, Drug-Induced, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00255879 is a Phase 1 study of Dyskinesia, Drug-Induced that has completed, run by University of California, San Diego. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00255879, a Phase 1 study of Dyskinesia, Drug-Induced, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
Conditions Studied
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
Study Locations (1)
California
- University of California, San Diego Division of Geriatric Psychiatry - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 1999-01 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255879
The ClinicalTrials.gov registry entry for NCT00255879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyskinesia, Drug-Induced appearing as the primary indexed condition, and to 3 interventions - of which Risperidone is the first listed.
NCT00255879 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00255879 about?
NCT00255879 is a clinical study titled "Movement Disorders Caused by Antipsychotic Drugs in Older Patients". This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
What is the current status of trial NCT00255879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 1999-01. Estimated completion is 2004-08.
What conditions does trial NCT00255879 study?
This clinical trial studies the following conditions: Dyskinesia, Drug-Induced.
What interventions are being tested in trial NCT00255879?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00255879?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00255879 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.